Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations

• Published in: Prostaglandins & other lipid mediators Vol. 82; no. 1; pp. 95 - 108
• Main Authors: Stitham, Jeremiah, Arehart, Eric J., Gleim, Scott R., Douville, Karen L., Hwa, John
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2007
• Subjects: Amino Acid Sequence; Asparagine - chemistry; Binding Sites; Cysteine - chemistry; Human prostacyclin receptor; Models, Molecular; Molecular Sequence Data; Mutagenesis; Mutation; Nuclear Magnetic Resonance, Biomolecular; Palmitic Acid - metabolism; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Polymorphisms; Proline - chemistry; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Epoprostenol - chemistry; Receptors, Epoprostenol - genetics; Receptors, Epoprostenol - physiology; Serine - chemistry; Human prostacyclin receptor; Mutagenesis; Polymorphisms
• ISSN: 1098-8823
• DOI: 10.1016/j.prostaglandins.2006.05.010

Prostacyclin (PGI 2) is released by vascular endothelial cells and serves as a potent vasodilator, inhibitor of platelet aggregation (anti-thrombotic), and moderator of vascular smooth muscle cell proliferation–migration–differentiation (anti-atherosclerotic). These actions are mediated via a seven transmembrane-spanning G-protein coupled receptor (GPCR), known as the human prostacyclin receptor or hIP. Animal studies using prostacyclin receptor knock-out (IP−/−) mice have revealed increased propensities towards thrombosis, intimal hyperplasia, atherosclerosis, restenosis, as well as reperfusion injury. Of further importance has been the world-wide withdrawal of selective COX-2 inhibitors, due to their discriminating suppression of COX-2-derived PGI 2 and its cardioprotective effects, leading to increased cardiovascular events, including myocardial infarction and thrombotic stroke. Over the last decade, mutagenesis studies of the IP receptor, in conjunction with in vitro functional assays and molecular modeling, have provided critical insights into the molecular mechanisms of both agonist binding and receptor activation. Most recently, the discovery of naturally-occurring and dysfunctional mutations within the hIP has provided additional insights into the proposed cardioprotective role of prostacyclin. The aim of this review is to summarize the most recent findings regarding hIP receptor structure–function that have developed through the study of both synthetic and naturally-occurring mutations.